Solta will be an IPO of approximately 30 percent of the business with the remainder to be held by BHC. Proceeds used to pay down debt. ($600 million if lucky) Then about $2.25 billion of debt will be taken on by the eye company and a portion of the eye company IPO’d in a traditional IPO. (Perhaps 25-30 percent).Those proceeds will the also pay down debt. The remainder of the eye company will be distributed out to BHC stockholders. This assumes they get enough out of these transactions to not swamp the remaining drug company with too much debt.notes from user $BHC, Bausch Health Companies Inc. / H1